<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26038738</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2222-1751</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China.</ArticleTitle><Pagination><StartPage>e30</StartPage><MedlinePgn>e30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/emi.2014.30</ELocationID><Abstract><AbstractText>Hand, foot and mouth disease (HFMD) is an important public health problem that has emerged over the past several years. HFMD predominantly infects children under seven years old and occasionally causes severe disease in adults. Among the enteroviruses, enterovirus 71 (EV71) and coxsackievirus 16 (CA16) are the major causative agents of HFMD. In addition, adenovirus cocirculates with enterovirus and has become a possible additional pathogenic factor for HFMD in some cases. Here, we have investigated the neutralizing antibody responses to both enterovirus and adenovirus in adults, with the aim of exploring the prevalence trends of these viruses and the nature of protective immunity in humans to these viral infections. Sera from 391 healthy adults from 21 provinces and cities in China were tested for the presence of antibodies against EV71, CA16, adenovirus human serotype 5 (AdHu5) and chimpanzee adenovirus pan7 (AdC7) using neutralization tests. High seroprevalence rates of EV71, CA16 and AdHu5 were found in the population (85.7%, 58.8% and 74.2%, respectively). The coseropositivity rate of these three viruses was 39.4% (154 of 391), with median neutralizing antibody titers of 80, 40 and 640, respectively, and the neutralizing antibody titer for EV71 was found to be correlated with those of CA16 and AdHu5. AdC7 was found to be a rare adenovirus serotype in the human population, with a seropositivity rate of 11.8%, suggesting that it could be a good choice for a vaccine carrier that could be used in vaccine development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Biology and Medical Sciences, Soochow University , Suzhou 215123, Jiangsu Province, China ; Vaccine Research Center, Institut Pasteur of Shanghai, Chinese Academy of Sciences , Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Man</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Institut Pasteur of Shanghai, Chinese Academy of Sciences , Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Institut Pasteur of Shanghai, Chinese Academy of Sciences , Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Institut Pasteur of Shanghai, Chinese Academy of Sciences , Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Yudan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Institut Pasteur of Shanghai, Chinese Academy of Sciences , Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Xinying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Institut Pasteur of Shanghai, Chinese Academy of Sciences , Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hongbo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Institut Pasteur of Shanghai, Chinese Academy of Sciences , Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Sidong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Biology and Medical Sciences, Soochow University , Suzhou 215123, Jiangsu Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Luogang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Suzhou Industrial Park Centers for Disease Control and Prevention , Suzhou 215123, Jiangsu Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Dongming</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Institut Pasteur of Shanghai, Chinese Academy of Sciences , Shanghai 200031, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AdC7</Keyword><Keyword MajorTopicYN="N">AdHu5</Keyword><Keyword MajorTopicYN="N">CA16</Keyword><Keyword MajorTopicYN="N">EV71</Keyword><Keyword MajorTopicYN="N">hand, foot and mouth disease</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26038738</ArticleId><ArticleId IdType="pmc">PMC4051363</ArticleId><ArticleId IdType="doi">10.1038/emi.2014.30</ArticleId><ArticleId IdType="pii">emi201430</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yu H, Wang M, Chang H, et al. Prevalence of antibodies against enterovirus 71 in children from Lu'an City in Central China. Jpn J Infect Dis. 2011;64:528&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">22116336</ArticleId></ArticleIdList></Reference><Reference><Citation>Toya M, Endo Y, Tanizaki H, Fujisawa A, Tanioka M, Miyachi Y. An adult case of severe hand-foot-mouth disease accompanying persistent fever and systemic arthritis. Dermatol Online J. 2012;18:14.</Citation><ArticleIdList><ArticleId IdType="pubmed">22948064</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi T, Fujisawa H, Sakai K, et al. Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult. Emerg Infect Dis. 2008;14:828&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600258</ArticleId><ArticleId IdType="pubmed">18439374</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, et al. Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol. 2009;47:2351&#x2013;2352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>De W, Changwen K, Wei L, et al. A large outbreak of hand, foot, and mouth disease caused by EV71 and CAV16 in Guangdong, China, 2009. Arch Virol. 2011;156:945&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pubmed">21305327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, Li L, Liu Y, et al. Seroepidemiology of human enterovirus 71 and coxsackievirusA16 in Jiangsu province, China. Virol J. 2012;9:248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3545860</ArticleId><ArticleId IdType="pubmed">23102275</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabenau HF, Richter M, Doerr HW. Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol. 2010;199:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">19941005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wang C, Xu L, et al. A laboratory evaluation of medicinal herbs used in china for the treatment of hand, foot, and mouth disease. Evid Based Complement Alternat Med: eCAM. 2013;2013:504563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3608275</ArticleId><ArticleId IdType="pubmed">23554831</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M, El Khatib NF, Tu S, et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol. 2012;53:285&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265829</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Liang ZL, Meng FY, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PloS ONE. 2012;7:e37206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3360679</ArticleId><ArticleId IdType="pubmed">22662137</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo ST, Chiang PS, Chao AS, et al. Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis. 2009;15:581&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671432</ArticleId><ArticleId IdType="pubmed">19331737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9:78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruohola A, Waris M, Allander T, Ziegler T, Heikkinen T, Ruuskanen O. Viral etiology of common cold in children, Finland. Emerg Infect Dis. 2009;15:344&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657644</ArticleId><ArticleId IdType="pubmed">19193292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa MJ, Krishnan S, Tio PH, Perera D, Wong SC. Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet. 1999;354:987&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">10501361</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006;194:1638&#x2013;1649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2428071</ArticleId><ArticleId IdType="pubmed">17109335</ArticleId></ArticleIdList></Reference><Reference><Citation>McElrath MJ, de Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372:1894&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774110</ArticleId><ArticleId IdType="pubmed">19012957</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Gao G, Reyes-Sandoval A, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol. 2002;76:2667&#x2013;2675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC135983</ArticleId><ArticleId IdType="pubmed">11861833</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Li Y, Cun A, et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis. 2006;12:1596&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3290939</ArticleId><ArticleId IdType="pubmed">17176582</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Huang X, Liu Q, Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013;31:2130&#x2013;2136.</Citation><ArticleIdList><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PloS ONE. 2013;8:e57601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprangers MC, Lakhai W, Koudstaal W, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003;41:5046&#x2013;5052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC262545</ArticleId><ArticleId IdType="pubmed">14605137</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Huang W, Zhou X, Zhao Q, Wang Q, Jia B. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol. 2013;85:1077&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pubmed">23588735</ArticleId></ArticleIdList></Reference><Reference><Citation>Davenport CB. Analysis of variance applied to human genetics. Proc Natl Acad Sci USA. 1940;1:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1077994</ArticleId><ArticleId IdType="pubmed">16577953</ArticleId></ArticleIdList></Reference><Reference><Citation>Spearman C. The proof and measurement of association between two things. Int J Epidemiol. 2010;5:1137&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">21051364</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrich S, Weinbrecht A, Schreier E. Seroprevalence and molecular epidemiology of enterovirus 71 in Germany. Arch Virol. 2009;154:1139&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">19506798</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Zhu S, Guo X, et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol J. 2010;7:300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989968</ArticleId><ArticleId IdType="pubmed">21050463</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Hsiung CA, Lu CY, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res. 2006;60:466&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7086547</ArticleId><ArticleId IdType="pubmed">16940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Deng C, Wan J, Zhu L, Leng Q. Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J. 2011;8:306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142239</ArticleId><ArticleId IdType="pubmed">21679417</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox JP, Hall CE, Cooney MK. The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol. 1977;105:362&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">192073</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorner AR, Vogels R, Kaspers J, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol. 2006;44:3781&#x2013;3783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1594810</ArticleId><ArticleId IdType="pubmed">17021110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostense S, Koudstaal W, Sprangers M, et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS. 2004;18:1213&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">15166541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010;28:950&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">19925902</ArticleId></ArticleIdList></Reference><Reference><Citation>Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004;11:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC371218</ArticleId><ArticleId IdType="pubmed">15013987</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005;174:7179&#x2013;7185.</Citation><ArticleIdList><ArticleId IdType="pubmed">15905562</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilankatta R, Chawla T, Khanna N, Swaminathan S. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J Med Virol. 2010;82:407&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">20087930</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbink P, Lemckert AA, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81:4654&#x2013;4663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1900173</ArticleId><ArticleId IdType="pubmed">17329340</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudareva M, Andrews L, Gilbert SC, et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine. 2009;27:3501&#x2013;3504.</Citation><ArticleIdList><ArticleId IdType="pubmed">19464527</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Zhou Y, Wu H, et al. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. J Med Virol. 2012;84:1408&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">22825819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Zhang Y, Feng L, et al. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine. 2011;29:3837&#x2013;3841.</Citation><ArticleIdList><ArticleId IdType="pubmed">21447314</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S, Kobinger GP, Lin J, et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine. 2007;25:6845&#x2013;6851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748222</ArticleId><ArticleId IdType="pubmed">17728024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobinger GP, Figueredo JM, Rowe T, et al. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine. 2007;25:5220&#x2013;5231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7115643</ArticleId><ArticleId IdType="pubmed">17559989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006;346:394&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">16356525</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>